Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 8, 2025
AVITA Medical Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025 …
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …
Metsera to Present at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit …
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
GlobeNewswire
·
May 8, 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GlobeNewswire
·
May 8, 2025
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
May 8, 2025
– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed …
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
GlobeNewswire
·
May 8, 2025
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in …
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter …
Teknova Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., …
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 8, 2025
Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU …
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire
·
May 8, 2025
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual …
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
GlobeNewswire
·
May 8, 2025
Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model In vitro data reported from new preclinical study …
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH- …
Jushi Holdings Inc. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Retail-First Growth Strategy Continues with 40 Operational Locations Nationwide at Quarter-End and Five Additional Stores Expected to Open by Year-End Strengthened Balance Sheet Through Strategic Transactions to Support Continued Expansion Net Loss of $17. …
Pacira BioSciences Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
-- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of …
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
GlobeNewswire
·
May 8, 2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European …
DLH to Continue Providing R&D and Advanced Technology Services to the Telemedicine and Advanced Technology Research Center
GlobeNewswire
·
May 8, 2025
ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security, today …
FoLix By Lumenis Recognized for Dermatology Innovation in 2025 MedTech Breakthrough Awards Program
GlobeNewswire
·
May 8, 2025
LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market, today announced …
Merus participera à la conférence BofA Securities 2025 sur les soins de santé
GlobeNewswire
·
May 8, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 08 mai 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques (Biclonics® et Triclonics®), a annoncé …
Merus hält einen Vortrag auf der BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 8, 2025
UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute …